PMRT delays early sensory recovery after DIEP flap breast neurotization
Postmastectomy radiation therapy can blunt the early neurologic gains surgeons hope to preserve in DIEP flap breast reconstruction with superficial neurotization. In this retrospective series of 135 patients treated between August 2019 and August 2024, 27 received PMRT and 108 did not, allowing a direct look at how irradiation changes the sensory trajectory after an operation designed to reconnect breast skin to a donor nerve pathway.
The clinical question is straightforward at the bedside. If a reconstruction is built around restoring cutaneous sensation, does radiation erase that effort or simply delay it?
Early thresholds were worse in irradiated patients, but recovery continued
Sensory testing with Semmes-Weinstein monofilaments showed substantial loss of sensation in both groups when compared with the normal breast. In the PMRT cohort, thresholds measured 31.51 ± 81.70 g versus 0.07 ± 0.19 g in the normal breast, while the non-PMRT group measured 14.62 ± 54.27 g versus 0.07 ± 0.17 g; both differences were highly significant at p < 0.001. Preoperative thresholds were similar between groups, with 0.10 ± 0.23 g in the PMRT group and 28.49 ± 85.76 g in the non-PMRT group, p = 0.950.
The early postoperative period carried the clearest penalty. At 0 to 6 months, the PMRT group had worse sensory thresholds than the non-PMRT group: 158.27 ± 140.97 g versus 58.11 ± 98.37 g, p = 0.007. By 19 to 24 months, the gap had narrowed to the point of non-significance, with 1.40 ± 2.20 g in the PMRT group and 2.76 ± 13.90 g in the non-PMRT group, p = 0.389.
Radiation did not permanently block sensory return; it slowed the path back.
Why irradiated tissue regains sensation more slowly
The pattern fits the biology of both radiation injury and nerve regeneration. PMRT can stiffen tissue, alter microvascular supply, and create a fibrotic environment that is less friendly to axonal growth and sensory receptor recovery. Superficial neurotization depends on coaptation between the reconstructed flap and the preserved nipple and skin territory, so any process that increases fibrosis or compromises local tissue pliability can delay the functional integration of that nerve repair.
The practical implication is not that neurotization fails in irradiated patients. It means the nerve repair may need more time to express its benefit, particularly in the first postoperative months when patients are most sensitive to numbness, altered touch, and concern that the breast mound feels disconnected from the body.
Patient-reported outcomes lagged behind the objective sensory curve
The questionnaire data mirrored the physiology only partly. Nipple sensation scores and sensory-related BREAST-Q domains did not differ significantly between the PMRT and non-PMRT groups. Even so, the irradiated cohort reported modestly lower psychosocial well-being, 36.95 ± 9.98 versus 41.68 ± 7.35, p = 0.042, and lower satisfaction with breasts, 42.64 ± 9.34 versus 48.65 ± 8.15, p = 0.036.
Those differences matter because they show how subjective recovery can remain sensitive to the history of cancer treatment even when objective sensory testing starts to converge. A breast that gradually regains light touch may still be experienced as less natural if the patient knows it has been through radiation, surgery, and reconstruction. The sensory endpoint is only one part of the lived outcome.
Complications and revisions did not rise with PMRT
Despite the early sensory delay, PMRT did not clearly worsen the surgical burden in this cohort. Complication rates were not significantly increased, and the need for secondary revision procedures also did not differ meaningfully between groups. For reconstructive planning, that finding is as important as the sensory data itself because it suggests that adding neurotization in an irradiated setting does not come with an obvious penalty in short-term reconstructive safety.
That matters for counseling. Patients who will need PMRT should not be told that neurotization is futile. They should be told the nerve recovery curve is slower and that the earliest months may look discouraging before later improvement becomes visible.
Sensory convergence by 13 to 18 months changes the counseling conversation
By 13 to 18 months after surgery, the study indicates that patients with PMRT reached sensory outcomes comparable to those without irradiation. This is the point at which the early signal from radiation appears to fade, at least in this cohort, and the reconstructed breast begins to behave more like a reinnervated breast than a radiated one.
For surgeons, that creates a more nuanced expectation for follow-up. A patient who feels little in the first half-year after surgery is not necessarily on a failed trajectory. The data support a longer horizon for sensory recovery, especially when PMRT is part of the oncologic sequence.
What this retrospective series can and cannot prove
The study is retrospective, and the PMRT group was much smaller than the non-PMRT group, with 27 irradiated patients versus 108 non-irradiated patients. That imbalance limits how confidently the findings can be generalized across every reconstruction pathway, radiation field, or timing sequence. The work also relies on monofilament testing and questionnaire-based patient-reported outcomes, both of which are useful but cannot fully capture the complexity of sensation, cortical adaptation, and daily breast perception.
Even with those limitations, the clinical message is consistent across the dataset: PMRT slows early sensory recovery after superficial neurotization in DIEP flap breast reconstruction, but the deficit narrows with time and no longer appears clinically meaningful by later follow-up. The challenge now is less about whether neurotization can work after radiation and more about how to optimize the timing, technique, and counseling around a treatment sequence that forces reconstruction to coexist with oncologic therapy.